Top 20 Papers from ESMO Open

Since launch ESMO Open has published over 280 articles which have received over 760,000 downloads globally. To showcase the breadth of content published in the journal, the ESMO Open editorial team have selected their top 20 articles comprising of some of the most cited, most read, top Altmetric scoring and most downloaded articles to share with you.

You can also find a list of the top cited articles of 2017 here.

Original Research
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients
Negrouk A, Lacombe D, Cardoso F, et al
10.1136/esmoopen-2017-000187

Original Research
Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
O’Dolly S, Migali C, Tunariu N, et al
10.1136/esmoopen-2016-000101

Original Research
Multiple primary tumours: challenges and approaches, a review
Vogt A, Schmid S, Heinimann, et al
10.1136/esmoopen-2017-000172

Original Research
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases
Siravegna G, Geuna E, Mussolin B, et al
10.1136/esmoopen-2017-000253

Original Research
Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
Dafini U, Karlis D, Pedeli X, et al
10.1136/esmoopen-2017-000216

Original Research
Global cancer control: responding to the growing burden, rising costs and inequalities in access
Prager GW, Braga S, Bystricky B, et al
10.1136/esmoopen-2017-000285

Original Research
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
Patil VM, Noronha V, Joshi A, et al
10.1136/esmoopen-2017-000168

Original Research
Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials
Patsou ED, Alexias GD, Anagnostopoulos FG, et al
10.1136/esmoopen-2017-000271

Review
Biology of premature ageing in survivors of cancer
Cupit-Link MC, Kirkland JL, Ness KK, et al
10.1136/esmoopen-2017-000250

Review
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
Morgan G, Lambertini M, Kourie HR, et al
10.1136/esmoopen-2016-000107

Review
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Granier C, De Guillebon E, Blanc C, et al
10.1136/esmoopen-2017-000213

Review
Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion
Preusser M, Winkler F, Valiente M, et al
10.1136/esmoopen-2017-000262

Review
Cardiotoxicity of immune checkpoint inhibitors
Varricchi G, Galdiero MR, Marone G, et al
10.1136/esmoopen-2017-000247

Review
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
Blackhall F, Camidge DR, Shaw AT, et al
10.1136/esmoopen-2017-000219

Review
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
Kitano A, Ono M, Yoshida M, et al
10.1136/esmoopen-2016-000150

Review
Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence
Polk A, Kolmos IL, Kümler I, et al
10.1136/esmoopen-2016-000093

Review
Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options
Ay C, Kamphuisen PW, Agnelli G, et al
10.1136/esmoopen-2017-000188

Review
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
Tabernero J, Vyas M, Giuliani R, et al
10.1136/esmoopen-2016-000142

Special Article
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Dittrich C, Kosty M, Jezdic S, et al
10.1136/esmoopen-2016-000097

Review
New treatment options for metastatic renal cell carcinoma
Rodriguez-Vida A, Hutson TE, Bellmunt J, et al
10.1136/esmoopen-2017-000185